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γ-Tocotrienol induces apoptosis in
pancreatic cancer cells by upregulation of
ceramide synthesis and modulation of
sphingolipid transport
Victoria E. Palau1,2, Kanishka Chakraborty1, Daniel Wann3, Janet Lightner1, Keely Hilton1, Marianne Brannon4,
William Stone4 and Koyamangalath Krishnan1*

Abstract
Background: Ceramide synthesis and metabolism is a promising target in cancer drug development. γ-tocotrienol
(GT3), a member of the vitamin E family, orchestrates multiple effects that ensure the induction of apoptosis in
both, wild-type and RAS-mutated pancreatic cancer cells. Here, we investigated whether these effects involve
changes in ceramide synthesis and transport.
Methods: The effects of GT3 on the synthesis of ceramide via the de novo pathway, and the hydrolysis of
sphingomyelin were analyzed by the expression levels of the enzymes serine palmitoyl transferase, ceramide
synthase-6, and dihydroceramide desaturase, and acid sphingomyelinase in wild-type RAS BxPC3, and RAS-mutated
MIA PaCa-2 and Panc 1 pancreatic cancer cells. Quantitative changes in ceramides, dihydroceramides, and
sphingomyelin at the cell membrane were detected by LCMS. Modulation of ceramide transport by GT3 was
studied by immunochemistry of CERT and ARV-1, and the subsequent effects at the cell membrane was analyzed
via immunofluorescence of ceramide, caveolin, and DR5.
Results: GT3 favors the upregulation of ceramide by stimulating synthesis at the ER and the plasma membrane.
Additionally, the conversion of newly synthesized ceramide to sphingomyelin and glucosylceramide at the Golgi is
prevented by the inhibition of CERT. Modulation ARV1 and previously observed inhibition of the HMG-CoA
pathway, contribute to changes in membrane structure and signaling functions, allows the clustering of DR5,
effectively initiating apoptosis.
Conclusions: Our results suggest that GT3 targets ceramide synthesis and transport, and that the upregulation of
ceramide and modulation of transporters CERT and ARV1 are important contributors to the apoptotic properties
demonstrated by GT3 in pancreatic cancer cells.
Keywords: γ-Tocotrienol, Vitamin E, Pancreatic cancer, ARV-1, CERT, Ceramide transport, Ceramide synthesis,
Ceramide distribution, Lipid transport, Membrane lipid, Free radicals
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Background
Pancreatic cancer is the fourth leading cause of cancerrelated deaths in the United States [1]. Since available
treatment options are limited, novel therapeutic agents
that demonstrate the ability to inhibit signaling pathways
implicated in the proliferation and survival of pancreatic
cancer cells need to be evaluated for drug development.
Promising agents may uncover new targets and alternate
treatment strategies that have the potential to contribute
to the understanding of pancreatic carcinogenesis and
progression. It has been known for a long time that ceramides can inhibit cell proliferation and induce apoptosis
in cancer cells via various stress stimuli such as tumor necrosis factor-α and platelet-activating factor [2, 3]. Furthermore, recent studies in the synthesis and metabolism
of ceramides suggest that changes in the expression levels
of these compounds may contribute to metastasis and resistance to therapy [4]. The syntheses of ceramides occur
through multiple pathways that include: de novo synthesis
from serine and palmitoyl-CoA substrates, salvage, from
sphingosine [5] and from the hydrolysis of sphingomyelin
by acid sphingomyelinase (ASM). The de novo synthesis is
initiated in the cytoplasmic face of the endoplasmic
reticulum by serine palmitoyl transferase (SPT), to form
3-keto-sphinganine, which is subsequently reduced to
sphinganine (SA). Ceramide synthase (CerS) acetylates SA
followed by desaturation by ceramide desaturase (DES) to
form ceramide [6, 7]. There are six CerSs that regulate
ceramide synthesis to produce a variety of compounds
with di-and tri-hydroxy long-chain bases linked to fatty
acids of variable length [8] and with C16 and C24 ceramides being most abundant in mammalian cells. These
highly hydrophobic molecules can displace cholesterol
and disrupt lipids rafts that may be associated with signaling molecules, thus affecting their function [9]. Moreover,
the biophysical properties of ceramides may influence
lipid reorganization in the membrane and cause
destabilization, efflux and fusion. Hence, their expression
levels and localization are tightly controlled.
Tocotrienols are members of the vitamin E family that
unlike tocopherols possess an unsaturated isoprenoid
side-chain [10]. These compounds have shown cytotoxic
activity on pancreatic cancer cells via a multi-pronged
mechanism. We had previously shown that γ-tocotrienol
(GT3) is cytotoxic to pancreatic cancer cells, and is significantly more potent in its ability to inhibit cell viability as
compared to alpha-tocopherol [11]. The ability of tocotrienols to selectively inhibit the PI3 kinase/Akt pathway,
Ras/Raf/Erk signaling [11], HMG CoA reductase, and
transcription factor NF-κB [12], are contributors to these
properties. In pancreatic cancer, the oncogenic process is
frequently driven by aberrant K-Ras. We have shown that
GT3 can cause inhibition of cellular proliferation and survival in pancreatic cancer cells regardless of their K-Ras
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status [11]. However, the mechanism of action is not completely understood. It has been reported that vitamin E isoforms other than tocotrienols can increase cellular ceramide
and dihydroceramide levels. Alpha-TEA, a modified form of
alpha tocopherol, can increase membrane ceramide levels in
mammary cancer cells [13], and γ-tocopherol has a similar
effect on prostate cancer cells [14]. In vivo, pharmacokinetics
studies have demonstrated the bioavailabilty of tocotrienols
in humans [15]. These studies led us to determine whether
the observed apoptotic effects in pancreatic cancer cells
dosed with GT3 involved changes in ceramide transport and
levels in K-Ras mutated cells as compared to wild type. Here
we show that GT3 causes an increase in the levels of certain
ceramides at the plasma membrane by the upregulation of
enzymes involved in both the de novo pathway and the hydrolysis of sphingomyelin, and the modulation of ceramide
transporters regardless of K-Ras status. The apoptotic nature
of these changes is confirmed by the clustering of death receptor 5 at the membrane and confirming previous observations of the mechanism of action by which GT3 inhibits cell
proliferation and survival in pancreatic cancer cells.

Methods
Cell lines and culture conditions

MIA PaCa-2 (CRM-CRL-1420), BxPc3 (CRL-1687), and
Panc 1 (CRL-1469) cells were obtained from the American
Type Culture Collection (Manassas, VA) and were maintained as described before [11]. Human pancreatic ductal
epithelial cells (HPDE-E6E7), a generous gift from Dr.
Ming-Sound Tsao (Ontario Cancer Institute, Toronto,
Ontario, Canada), were cultured in keratinocyte medium
(Fisher Scientific, Waltham, MA) as described elsewhere
[16]. For immunoblotting experiments, lentiviral transduction, LC/MS and qRT-PCR, cells were seeded on 60 mm
plates at high density (~5x104 cells/cm2) to obtain
confluency in 2–3 days. For immunofluorescence
experiments, the cells were seeded on 12mm round cover
slips (Fisher Scientific) or 6-mm Transwell-ClearTM filters
(Corning Costar) at high density (~5x104 cells/cm2) and
treated at 70% confluency.
SDS PAGE and immunoblotting

Cells (70% confluent) were treated with GT3 (Cayman
Chemical, Ann Arbor, MI) dissolved in ethanol, at a concentration of 40 μM or dissolution vehicle as a control
and incubated for 2, 4, or 6 hours. The cells were rinsed
with phosphate-buffered saline and lysed in the plate
with buffer (20 mM Imidazole-HCl, pH 6.8, 100 mM
KCl, 1 mM MgCl2, 10 mM EGTA, 0.2% (v/v) Triton X100,) containing phosphatase and protease inhibitors
(Sigma Aldrich, St. Louis, MO). The protein concentration of the cell lysates was determined using the Advanced protein assay reagent (Cytoskekleton, Denver,
CO). Equal amounts of proteins in cell lysates were
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separated in 7 or 10% SDS-PAGE. The proteins were
transferred to nitrocellulose membranes (Pall Life Sciences, Ann Arbor, MI). Immunoblot procedures were
done according the protocol for each antibody. Membranes were probed with primary antibodies against
ASM, DEGS1, SPT, Collagen type IV alpha-3-binding
protein, also known as ceramide transfer protein CERT,
DDIT3 (Abcam, Cambridge, MA), ceramide synthase 6
(Abgent, San Diego, CA), ACAT-related enzyme-2 required for viability, also known as ARV1 (Santa Cruz
Biotechnology, Dallas, TX), DR5 (Sigma Aldrich), and
caveolin (Cell Signaling Technology, Danvers, MA).
Lentiviral transduction of ARV1 shRNA

shRNA-expressing lentiviral particles against human
ARV1 (NM_022786) were obtained from Sigma Aldrich
(5’CCGGGCCAGAAACCTGTAGACAAATCTCGAGA
TTTGTCTACAGGTTT CTGGCTTTTTG-3’) clone no.
TCRN0000107011; MIA PaCa-2 cells were transduced at
70% confluency and treated with GT3 or dissolution vehicle, 48h after lentiviral transduction.
qRT-PCR for ARV-1 and ceramide enzymes
To study the levels of ARV1, quantitative RT-PCR was
performed on MIA PaCa-2 cells. Total RNA was isolated
using Trizol (Invitrogen) according to the manufacturer's
instructions and treated with DNase I using the RNeasy
Mini Kit and on-column RNase free DNase kit (Qiagen).
1.0 μg RNA was reverse-transcribed with the Super script
II Kit (Invitrogen) as recommended. The ARV-1 primers
used were: (GCC ACC ACC TCA GGT ATG CTT C)
and (GTG CAA AGC TCA GGC CTA CAG AC).
Immunofluorescence

Cells were dosed with 40μM GT3 or ethanol as a control
and processed for immunofluorescence as described before [17]. Briefly, cells were rinsed with phosphatebuffered saline and fixed with 4% p-formaldehyde. Then
the cells were rinsed and permeabilized with 0.2%
Triton-X100, followed by quenching with NH4Cl. Cells
were then incubated with primary antibody in 1% bovine
serum albumin at room temperature for one hour. Antibodies against ceramide, death receptor 5 (DR5) (Sigma)
and caveolin (Cell Signaling Technology) were used as
primary antibodies for immunofluorescence. Cells were
then rinsed and incubated for one hour in the dark with
secondary antibody conjugated to fluorescent dyes Alexa
Fluor 488® and Texas Red® (Molecular Probes, Eugene,
OR). DAPI stain was used to visualize nuclei. Cells were
then mounted in 10% polyvinyl alcohol, 30% glycerol,
1% n-propyl gallate and SlowFadeTM (Molecular Probes).
Laser confocal microscopy was performed with a Zeiss
LSM 710 confocal microscope (Carl Zeiss MicroImaging
GmbH, Germany) in the Imaging Core, Quillen College
of Medicine, East Tennessee State University. Cell
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monolayers were analyzed using a 63 x oil immersion
objective. The images were collected using the LSM 710
software (Carl Zeiss Micro Imaging).
Preparation of cellular samples for LC/MS

All solvents for sample extraction and LC/MS were LC/
MS grade (Fisher Scientific), other reagents were
purchased from Sigma-Aldrich (St. Louis, MO, USA) or
Fisher Scientific. Calibration standards and internal
standards were purchased from Avanti Polar Lipid, Inc.
(Alabaster, AL). Crude plasma membrane isolation was
carried out at 4°C. Briefly, cells were resuspended in lysis
buffer (NaHCO3 1mM, NaCO3 0.011mM, CaCl2 1mM,
MgCl2 1mM, pH 7.4), and incubated on ice for 20 minutes, followed by homogenization with a Dounce
homogenizer. The homogenates were centrifuged at 500 g
for 5 minutes; the resulting supernatant was transferred to
another microcentrifuge tube, and the remaining pellet
containing the nuclear fraction was discarded. An equal
volume of 510mM sucrose solution was added to the
supernatant, and separated by centrifugation at 20,000g
for 30minutes. The supernatant was transferred to an
ultracentrifuge tube, and the remaining pellet containing
mitochondria, Golgi apparatus and part of the microsome
was set aside. The supernatant was ultracentrifuged at
240,000 g for 2 hrs. The resulting supernatant was transferred to another tube as cytosol sample, whereas the
crude plasma membrane was settled in the pellet. The pellet was washed with lysis buffer and resuspended with
PBS as plasma membrane sample. Samples were frozen at
-80 C for later analysis. The extraction of lipids from the
plasma membrane was performed in the following manner, 1 ml of methanol containing 20μl of 2μM of each internal standard (C12 ceramides, C12 dihydroceramide,
C12 sphingomyelin, C17 sphingosine, C17 sphinganine,
C17 sphingosine-1-phosphate, and C17 sphinganine-1phosphate) were added to 100μl aliquot of sample in a
clean glass tube. The mixture was centrifuged at 3,000g
for 10 minutes and the supernatant was transferred to a
second glass tube and evaporated under a nitrogen
stream. The extracted lipids were reconstituted in methanol: acetonitrile (v:v=50:50) and transferred to LC/MS
autosampler vials (Waters, Milford, MA) for injection.
LC/MS

All experiments were carried out on a Waters Xevo TQ
MS ACQUITY UPLC system (Waters). The system was
controlled by Mass Lynx Software version 4. 1. The sample was maintained at 4°C in the autosampler and was
loaded onto a Waters ACQUITY UPLC BEH Phenyl column (3 mm inner diameter × 100 mm with 1.7 μm particles), preceded by a 2.1×5 mm guard column containing
the same packing. The column was maintained at 40°C
throughout analysis. The UPLC flow rate was
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continuously 300μL/min in a binary gradient mode with
the following mobile phase: initial flow conditions were
20% solvent A (H2O, containing 0.2% formic acid and 0.
1% ammonium formate) and 80% solvent B (acetonitrile,
containing 0.2% formic acid and 0.1% ammonium formate). Solvent B was increased linearly to 95% over a 2
min period and to 98% in the subsequent 6 min. This was
followed by a reduction of solvent B to 80% starting at 8.2
min and continuing through 9 min. Ceramides of interest
eluted between 4.0 and 7.5 min. Positive ESI-MS/MS mass
spectrometry was performed to identify ceramide species.
Different species were confirmed by comparing the retention times of experimental compounds with those of authentic standards. Concentrations of ceramides in the
samples were quantified by comparing integrated peak
areas for those of each ceramide against those of known
amounts of purified standards. Loss during extraction was
accounted for by adjusting for the recovery of the internal
standard added before extraction. Positive ESI-MS/MS
was performed using the parameters described under supplementary information.
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Statistical analysis. Data are represented as the mean ±
SE. In all cases, n refers to the number of independent experiments. When comparisons were done relative to the
control, statistical analyses were run by Student's t test, p <
0.05 was considered significant. Statistical significance of
comparisons between different treatments was assessed
using ANOVA (GraphPad Prism 7, La Jolla, CA).

Results
Upregulation of ceramide via the de novo pathway and
the hydrolysis of sphingomyelin by GT3 in pancreatic
cancer cells regardless of their Ras status. Previous studies had shown that apoptosis is induced by GT3 in both
wild type and mutated K-Ras pancreatic cancer cell lines
via a mechanism that involves disruption of signaling of
receptor tyrosine kinase ErbB2. To test whether changes
in ceramide expression levels occur, we probed the ceramide de novo synthesis pathway by analyzing the expression of enzymes SPT, CERS-6, DEGS1 at 2, 4, and 6
hours after dosing with GT3, K-Ras mutated MIA PaCa2 (Fig. 1a-f ) and Panc 1 (Fig. 2a-f ), and wild type BxPC3

Fig. 1 Time-dependent increase of ceramide synthesis enzymes in GT3 treated MIA-PaCa-2 cells.Ceramide is produced via the de novo pathway (a, c,
e) each step is catalized by the following enzymes, SPT(b), CER6 (d), and DEGS1(f). It is also produced by hydrolysis of sphingomyelin (g) by
ASM (h). Pancreatic cancer MIA PaCa-2 cells were treated with GT3 at a concentration of 40 μM or dissolution vehicle as a control for different
time periods (2, 4, 6 h). Cell lysates were analyzed by immunoblot. Membranes were incubated with antibodies against SPT(b), CERS6 (d),
DEGS1(f), and ASM(h). The membranes were reprobed with actin as a loading control. All assays were conducted at least three times and blots
shown are representative of the results obtained. For quantification band densities from the treatment conditions identified by the lane labels,
were calculated as percentages of the value for the treated, untreated cells (100%), and shown averages ± standard deviations from three
independent experiments (*p<0.05)
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Fig. 2 Time-dependent analysis of enzymes involved in ceramide synthesis in GT3 treated BxPC3, Panc 1 and HPDE-E6E7 cells. Pancreatic cancer cells
BxPC3(a-f), Panc 1 (g-l), and non-cancerous ductal pancreatic cells HPDE-E6E7 (m-r) were treated with GT3 at a concentration of 40 μM
or dissolution vehicle as a control for different time periods (2, 4, 6 h). Cell lysates were analyzed by immunoblot. Membranes were
incubated with antibodies against SPT, CERS6, and DEGS1. The membranes were reprobed with actin as a loading control (located below
each set of enzyme immunoblots, as in Figure 1). For quantification band densities from the treatment conditions identified by the lane
labels, were calculated as percentages of the value for the treated, untreated cells (100%). Data shown of representative experiments,
(mean ± SE, n = 3) *p<0.05, **p<0.01, significant difference between control and GT3 treated cells analyzed at different time points

pancreatic cancer cells (Fig. 2g-l). The expression levels
of all enzymes tested increased in a time-dependent
manner in MIA PaCa-2, Panc 1, and BxPC3 pancreatic
cancer cells. A 1.5 fold increase of SPT is apparent 2
hours after dosing MIA PaCa -2 cells with GT3 as compared to the control (Fig. 1a and b). Similarly, DEGS1
levels increase in all cell lines tested with up to 3.0 fold
increase in MIA PaCa-2 cells (Fig. 1e and f ). A robust
increase in the CERS6 levels at 4 and 6 hours after
treatment with GT3 also support the activation of this
pathway (Fig. 1c and d). Many recent studies have demonstrated the central role of ASM in the apoptotic
process via the formation of ceramide-enriched

membrane domains, specifically by gamma radiation
[18, 19], UV light [20, 21], and chemotherapeutic
agents such as cisplatin [22] and doxorubicin [23]. To
determine whether GT3 activates the hydrolysis of
sphingomyelin, we probed the levels of ASM. Our results indicate that GT3 may also favor the hydrolysis of
sphingomyelin to produce ceramide by increasing the
concentration of ASM by 3.4 fold in MIA PaCa-2 cells
after treatment with GT3 (Fig. 1g and h). A similar
trend on the levels of ASM was observed in Panc 1 and
BxPC3 pancreatic cancer cells (results not shown).
These results suggest that the activation of ceramide
synthesis by GT3 is likely to increase the ceramide
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levels in the treated cells. Conversely, in non-cancerous
human pancreatic ductal epithelial cells (HPDE-E6E7),
GT3 has no significant effects on any of the enzymes
tested, as compared to the control (Fig. 2m-r).
Pancreatic cancer cells MIA PaCa-2 have higher total ceramide content than non-malignant pancreatic HPDE-E6E7
epithelial cells and GT3 cause a further increase in ceramides and dihydroceramides in MIA PaCa-2 cells. Ceramide is an important regulator of cellular homeostasis,
involved in signaling pathways of apoptosis, senescence,
and differentiation [24]. However, its expression levels are
normally low and upregulation of ceramide concentration
is tightly controlled. Increased levels of ceramides are
known to cause apoptosis and are also involved in oncogenesis. To test whether pancreatic cancer MIA PaCa-2
cells have higher ceramide levels than epithelial pancreatic
HPDE-E6E7 cells, the total content of ceramides was analyzed by LCMS. The results obtained are in agreement with
previous studies in other cancers, and show that MIA
PaCa-2 cells have approximately three-fold expression
levels than non-malignant (HPDE-E6E7) pancreatic cells
(Fig. 3a). Further accumulation of ceramides in the cell
membrane may activate their apoptotic function, and support the observations in studies that have shown inhibition
of cell viability by GT3. LCMS analysis showed that GT3
cause a further increase of 72.9%±1.82 total membrane ceramides in MIA PaCa-2 cells, confirming the observations
on the activation of synthesis pathways of ceramide (Fig.
3b). Dihydroceramides are present at significantly lower
concentrations as compared to ceramides in both MIA
PaCa-2 and HPDE-E6E7 cells. Unlike ceramides, dihydroceramide levels in the membrane are three fold higher in
HPDE-E6E7 than in MIA PaCa-2 cells. These compounds
show an increase of 80.5 %±1.16, and 42.97%±3.47 after
treatment with GT3 of MIA PaCa-2 and HPDE-E6E7 cells,
respectively (Fig. 3b).
Membrane sphingomyelin is significantly decreased in
MIA PaCa-2 and HPDE-E6E7 cells treated with GT3. Besides the de novo pathway, ceramide synthesis can occur
via the hydrolysis of sphingomyelin. In order to determine
whether there is a significant change in sphingomyelin
content, LCMS analysis was conducted on cell lysates of
GT3 treated and untreated MIA PaCa-2 and HPDE-E6E7
cells. In untreated cells, non-malignant cells have only
slightly higher levels of sphingomyelin than pancreatic
cancer cells (Fig. 3c). A significant decrease in membrane
sphingomyelin of 26.54%±0.071 in MIA PaCa-2, and 70.
05% ±11.17 in HPDE-E6E7 was observed after treatment
with GT3, supporting our previous data on the activation
of the ceramide synthesis pathway via sphingomyelin hydrolysis (Fig. 3c).
GT3 cause an increase in membrane ceramides and
dihydroceramides C16, C24:1, and C24 and a decrease
in sphingomyelins in MIA PaCa-2 cells Ceramides with a

Page 6 of 14

Fig. 3 Analysis of the effect of GT3 treatment on cellular levels
of ceramide,dihydroceramide, and sphingomyelin. A. LC/MS analysis of
sphingolipids present in theplasma membrane for ceramides (a),
dihydroceramides (b), and sphingomyelin (c), in MIA Paca-2, and
HPDE-E6E7 cells treated with dissolution vehicle (control) or 40 μMGT3.
Results are shown as pmol of each indicated sphingolipid / mg of
protein in the sample analyzed. The values shown are the averages ±
standard deviations obtained from three independentexperiments. * p
<0.05, significant difference between control and GT3 treated cells

different fatty acid chain length, have different cellular
functions. It has been previously reported that increase
in the levels of C16, C24:1 and C24 ceramides, can induce cell death in lymphoma cells after treatment with
cannabinoids [25], and the specific upregulation of C16
ceramide in leukemia and colon cancer cells can cause
apoptosis [26]. To test whether membrane C16, C24:1,
and C24 ceramides are altered by GT3 treatment of
MIA PaCa-2 and HPDE E6E7 cells, we analyzed these
compounds by LC/MS. Our data show that in untreated
cells, C16 is present at 2.7-fold higher levels in MIA
PaCa-2 than in HPDE E6E7 cells. Similarly, C24:1, and
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C24 ceramides, are also present at 7.5-fold and 3.5 fold
higher levels in MIA PaCa-2 than in HPDE E6E7 cells.
Treatment with GT3 produce a significant change only
in C16 ceramide, with an increase of 32.36% as compared to the control (Fig. 4a). Conversely, in nonmalignant HPDE-E6E7 cells, the only membrane ceramide that is observed to change significantly is also
C16 with a 41.47% decrease as compared to the control
(Fig. 4b). Dihydroceramides are present at significantly
lower concentrations than ceramides in MIA PaCa-2
cells. However, these compounds may contribute to the
total content of cellular ceramides. Our results show that
GT3 cause an increase in dihydroceramides of 79.08%
87.34%, and 83.44% for C16, C24:1, and C24, respectively as compared to the control (Fig. 4c). HPDE-E6E7
cells have higher concentrations of dihydroceramides at
the cellular membrane than MIA PaCa-2 cancer cells.
Our results show that only C16 display a significant
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increase of 59.52% (Fig. 4d). All sphingomyelins tested
displayed a significant decrease in MIA PaCa-2 cells
after treatment with GT3. LCMS analysis of sphingomyelin in MIA PaCa-2 cells treated with GT3 showed a
significant decrease of 29. 2% (C16), 24.44 (C24:1), and
45.0% (C24). (Fig. 4e). Similarly to sphingomyelins in
MIA PaCa-2 cells, GT3 cause a significant decrease in
HPDE-E6E7 -E6E7 cells of 79.5% (C16), 74.8% (C24:1),
and 79.3% (C24) (Fig. 4f ).
Ceramide transporter CERT is downregulated and
ER-localized sterol transport protein ARV1 is upregulated by GT3 in MIA PaCa-2, BxPC3, and Panc1
pancreatic cancer cells.
To determine whether the activation of the pathways
of ceramide synthesis cause an effect on the expression
levels of ceramide transporters, we probed ceramide
transport protein CERT and ARV-1. The function of the
ceramide transport protein CERT, is to transport newly

Fig. 4 Analysis of the effect of GT3 treatment on the expression levels of ceramides C16, C24:1 and C24. A. LC/MS of C16, C24:1 and C24 ceramides in
MIA PaCa-2 cells (a), and HPDE-E6E7(b) dihydroceramides (c and d), and sphingomyelin (e and f ) treated with dissolution vehicle (control) or
40μM GT3. Results are shown as pmol of each indicatedsphingolipid/mg of protein in the sample analyzed. The values shown are the averages ±
standard deviations obtained from three independent experiments. * p <0.05, significant differencebetween control and GT3 treated cells
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synthesized ceramide from the ER to the Golgi [27],
where the latter is hydrolyzed to sphingomyelin by
sphingomyelinase [28]. To determine whether treatment
of MIA PaCa-2, BxPC3, and Panc 1 cancer cells with
GT3 favor the transport of newly synthesized ceramide
to the Golgi, the levels of CERT and its phosphorylated
form were probed by immunoblot. As shown in Fig. 5a
and b, there is a significant decrease of both, the activated form and total CERT levels in GT3 treated MIA
PaCa-2 cells as compared to the control. We also probed
ARV1, a sterol/ceramide transport protein that interacts
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with genes involved in GPI anchor synthesis; it has been
shown that GPI assembly is required for ceramide transport from the ER [29]. As shown in Fig. 5c, d and f,
ARV-1 displays a dose-dependent increase in expression
levels in MIA PaCa-2, BxPC3 and Panc 1 cells treated
with GT3 at 5, 10, 20, and 40μM, with ARV-1 expression levels reaching a 3-fold increase at the highest concentration tested in MIA PaCa-2 cells. A similar trend
was observed in BxPC3 and Panc 1 cells, suggesting a
decrease in sphingomyelin biosynthesis from newly synthesized ceramide (Fig. 5g).This trend is also evident in

Fig. 5 Downregulation of ceramide transporter CERT and upregulation of transport protein, ARV-1 in MIA PaCa-2, BxPC3, Panc 1 and HPDE-E6E7 cells
treated with GT3. Pancreatic cancer cells MIA PaCa-2, BxPC3, and Panc 1, as well as HPDE-E6E7cells were treated for 4 hours with increasing
concentrations of GT3 over a dose range from 0-40μM and probed for CERT and its activated form (a and b for MIA PaCa-2 assays, and g for
BxPC3, Panc1, and HPDE-E6E7), ARV-1 (c and d for MIA PaCa-2 assays and f for BxPC3, Panc1, and HPDE-E6E7), and analyzed by western immunoblot. The membranes were reprobed with actin as a loading control. Quantitative RT-PCR using ARV-1 primers was performed on MIA PaCa-2 cells
treated with increasing concentrations of GT3 in the same manner as described above (e). All assays were conducted in triplicate and blots
shown are representative of the results obtained. For quantification, (graphs) band densities from the treatment conditions identified by the lane
labels, were calculated as percentages of the value for the treated, untreated cells (100%). Data shown of representative experiments, (mean ± SE,
n = 3). * p <0.05, significant difference between control and GT3 treated cells at different concentrations
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rtPCR analysis suggesting that GT3 effect on ARV-1
may occur at the transcription level (Fig. 5e).
GT3 treatment of ARV-1 inhibited MIA PaCa-2 cells
causes upregulation of the expression levels of caveolin-1. To
test whether the effect of GT3 on ARV-1 occurs mainly at
the messenger level, protein expression levels were analyzed
by immunoblot in MIA PaCa-2 cells transduced with ARV1 shRNA and treated with GT3. As shown in Fig. 6a and b,
ARV-1 is effectively downregulated by ARV-1 shRNA (Fig.
6a and b). GT3 has no significant effect on the expression
of ARV-1 (Fig. 6a and b). One of the functions of ARV-1 is
to regulate sterol trafficking and plasma membrane
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structure. It is also known that ceramide is present in caveolae in cancer cells. To test whether GT3 has an effect on
caveolin-1, we probed the expression levels of this protein
in the presence and in the absence of ARV-1 in MIA PaCa2 cells. Data shown in Fig. 6c and d suggest that in the presence of ARV-1, there is no significant change in the expression levels of this molecule. However, substantial
upregulation is observed in the absence of ARV-1 regardless
of GT3 treatment. Caveolin-1 is present in caveolae and is a
major component of the vesicular transport system of the
trans-Golgi network [27]. To study the role of ARV-1 in the
localization of ceramide and caveolin in GT3 treated cells,

Fig. 6 GT3 effect on ARV-1 knockdown MIA PaCa-2 cells. MIA PaCa-2 cells were transduced with ARV-1 shRNA lentiviral particles, and then treated
with 40μM GT3 or dissolution vehicle (control). Cell lysates were analyzed by immunoblot with antibodies against ARV-1 (a,b) caveo lin (c,d). The
membranes were reprobed with actin as a loading control. Data shown of representative experiments, (mean ± SE, n = 3). * p <0.05, significant
difference between control and treated cells in different conditions (One-way ANOVA with Bonferroni’s test). e. Expression and localization of
ceramide and caveolin in ARV-1 knockdown MIA PaCa-2 cells treated with vehicle (control) or 40μM GT3, and processed for immunofluorescence.
Single confocal sections are shown in the x-y plane, ceramide (red channel), caveolin (green channel), and DAPI (blue channel)
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ARV-1 shRNA transduced cells were processed for immunofluorescence. In the absence of ARV-1, caveolin
(green channel) and ceramide (red channel) are localized at
the plasma membrane and intracellularly in GT3 treated
cells (Fig. 6e).
Ceramide-rich caveolae favor clustering of DR5 in GT3
treated pancreatic cancer cells. It has been reported that a
high presence of ceramide in caveolae in human colon
cancer cells, favors apoptosis via clustering of Death Receptor 5 [28]. We have previously shown that GT3 has a
potent inhibitory effect on ErbB2 phosphorylation [11].
Since ErbB2 is co-localized with caveolin [30], we probed
whether the increase of membrane ceramides and the onset of apoptosis by GT3 include the clustering of DR5, by
determining the presence and localization of the receptor
via immunofluorescence. In untreated and treated cells,
ceramide and DR5 are localized at the membrane, red and
green channels respectively, Fig. 7a xy and xz planes. Intensity correlation analysis of 14 fields, each with an average of 12.5 cells, showed no significant change with a
percentage of colocalization of 74.6% in untreated cells
(Fig. 7b) and 73.8% in treated cells (Fig. 7d). However,
there was a substantial increase in fluorescence intensity
on treated cells, of 3-fold for DR5, and 1.5-fold for ceramide (Fig. 7e) as compared to the control (Fig. 7c). To
confirm these observations, analysis of mean intensities of
the red and green channels was conducted in these cells
(Fig. 8a) GT3 treated cells showed a significant increase in
intensities of both channels as compared to untreated cells
(Fig. 8b). These results suggest that the activation of apoptosis by GT3 in pancreatic cancer cells may include the
participation of DR5 and an increase of ceramide expression levels at the cell membrane suggesting the presence
of ceramide micro domains that have been described
previously [31].

Discussion
Our previous work indicated that GT3 has potent antiproliferative activity in both k-Ras wild type and k-Ras
mutated pancreatic cancer cells, but not on noncancerous pancreatic duct epithelial HPDE-E6E7 cells.
The mechanism of action included inhibitory effects on
transcription factor NF-κB [12], ErbB2, and the PI3K,
MAPK, and HMG CoA reductase pathways, as well as induction of apoptotic signaling through Foxo3 and GSK-3β
[11]. However, the coordination of these multi-pronged effects is not completely understood. The results presented
in this study suggest that the modulation of expression
and localization of ceramide is a relevant factor contributing to the previously observed effects on cell signaling
pathways and cell survival. The increase of expression of
ASM, responsible for the production of ceramide from
sphingomyelin, lends support to this notion. ASM localizes in sphingolipid and cholesterol-enriched membrane
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domains [32], and the ceramide molecules thus generated,
freely associate with each other forming strongly stabilized
[33] ceramide-enriched membrane domains [25] by the
selective displacement of cholesterol [9]. These changes in
membrane composition alter the relatively rapid lateral
diffusion characteristic of cholesterol-rich liquid-ordered
state [26], and cause destabilization in the structure and
function of membrane domains where ErbB2 and other
signaling molecules are known to be localized. We had
previously shown that cholesterol depletion result in the
loss of ErbB2 activation and subsequent inhibition of the
ERK pathway [17] It has also been shown that ceramide
can cause apoptosis via inactivation of the Ras-Raf/MEK
pathway [34]. Thus the exclusion of cholesterol from the
plasma membrane, and the downregulation of cholesterol
synthesis through inhibition of the HMG CoA reductase
pathway by GT3, are likely contributors to the profound
changes at the cell membrane imposed by the upregulation of ceramide synthesis. Furthermore, ASM activity also
leads to cholesterol displacement from the plasma membrane [35–38] supporting a shift in membrane composition and structure, and subsequently altering signaling
function. The resulting ceramide-enriched membrane domains [31], may then favor the presence and clustering of
death receptors [28, 39], in agreement with our observation of DR5 localization and clustering at the plasma
membrane. These events are required for the formation of
death-inducing signaling complexes [40, 41] and are indicative of the activation of the extrinsic apoptotic (JNK)
pathway [42], which lend support to our previous results
on the upregulation and activation of c-JUN and caspase 8
by GT3 [11]. The role of ceramide in the activation of the
JNK pathway and initiation of apoptosis has been demonstrated in several studies [43, 44]. Additionally, DR5 is a
component of the TRAIL apoptotic signaling, important
for its selective toxicity towards tumor cells [45] and its
relation to resistance and sensitization to chemotherapy
agents [46]. Our results suggest that GT3 cytotoxic effects
carried out via various signaling molecules, are facilitated
by the upregulation of expression levels of enzymes involved in the synthesis of ceramide and the subsequent
shift in cellular membrane composition and function.
However, this set of finely orchestrated events that may
obviate the aberrant survival mechanisms present in pancreatic cancer cells, would not be functional without the
upregulation of ARV-1 [47] and downregulation of CERT.
ARV-1 is involved in sterol transport [48] as well as
sphingolipid [49] and glycosylphosphatidyl- inositol [29]
biosynthesis. Thus suggesting that GT3 may exert an effect on multiple targets related to control of transcription
and molecular synthesis, as well as lipid trafficking and
distribution. Loss of membrane cholesterol stimulate
sphingolipid transport via CERT [36], and changes in
membrane composition by the increase in ceramide
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Fig. 7 Colocalization analysis of ceramide and DR5 after GT3 treatment in MIA PaCa-2 cells. MIA PaCa-2 cells were treated with dissolution vehicle (a
top panels ) or 40μM GT3 (a bottom panels), fixed, and processed for immunofluorescence. Single confocal sections shown in the x-y plane, and
3D reconstructions of the confocal stack in the x–z plane perpendicular to the monolayer, apical side up, show localization of DR5 (green channel), ceramide (red channel), and nuclei using DAPI (blue channel). Intensity correlation analysis of 14 fields, each with an average of 12.5 cells
from at least three independent experiments, using the Leica Software were run for control cells (b) and (c) and treated cells (d) and were plotted
for both sets of cell populations. The values shown are the averages ± standard deviations obtained from at least three independent experiments.
Images are representative of fields analyzed. Graphs illustrating the quantification of relative fluorescence for control cells (c) and treated cells (e)
show the merge for ceramide and DR5 channels. Images shown are representative of the fields observed

content, cause displacement of cholesterol [9]. However,
GT3 effectively downregulates CERT, thus causing inhibition of sphingomyelin synthesis in the Golgi from ceramide by diminishing the transport of newly produced
ceramide from the ER [50, 51]. Additionally, upregulation
of sterol transporter ARV-1, and ceramide synthesis enzymes cause redistribution and upregulation of ceramide

at the cellular membrane strongly promoting a profound
change in membrane composition and function. Thus,
GT3 displays remarkable efficacy in inhibiting the survival
mechanisms present in pancreatic cancer cells by its direct
involvement in multiple pro-apoptotic events. Specifically,
the inhibition of the MAPK and PI 3K/AKT pathways affecting proliferation and survival, the activation of GSK3β
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Fig. 8 Fluorescence intensity analysis of ceramide and DR5 after GT3 treatment in MIA PaCa-2 cells. a MIA PaCa-2 cells were treated with dissolution
vehicle (A, top panels ) or 40μM GT3 (A, bottom panels), fixed, and processed for immunofluorescence. Single confocal sections shown in the x-y plane,
show localization of DR5 (green channel), ceramide (red channel), and nuclei using DAPI (blue channel). b The fluorescence intensities along the white
lines indicated in the merged pictures were quantified using the line scan application of Leica software. Data obtained from line scans drawn through
the cell were plotted in a graph and expressed as mean ±SE, n= 50 cells, from three independent experiments.*p < 0.05

and Foxo3 translocation to the nucleus causing G1-phase
cell cycle arrest, and activation of the JNK apoptotic pathway via upregulation of and clustering of DR5 at the cell
membrane, with subsequent phosphorylation of c-JUN
and activation of caspases (10). Additionally, the increase
of synthesis of ceramides, specifically, C:16 ceramide a
pro-apoptotic molecule. Since most of the newly synthesized ceramides in the ER are used in the Golgi for the
synthesis of sphingomyelin and glycosphingolipids [52],
the inhibition of CERT [50] causes accumulation of ceramides at the ER, favoring cellular stress and apoptosis.
Previous studies have shown increased cytotoxic effects by
upregulation of ceramide synthesis in cancer cells.
However, tumor cells treated with drugs that target one
or two of the pathways, are likely to fail. Eight approaches
to raise ceramide levels have been identified, and many
studies suggest that a multiple approach is best to attain a
successful intervention [53]. This study has shown that
GT3 effectively addresses four of these: stimulation of ceramide synthesis by the de novo pathway and sphingomyelin

hydrolysis, inhibition of glycoceramide and sphingomyelin
synthesis from ceramide. The latter is due to the inhibition
of CERT and results in the downregulation of the MDR1
[54] suggesting the involvement of ceramide with the multidrug resistance pathway. The mechanism of action of
several current chemotherapeutic agents include the upregulation of cellular levels of ceramide. Treatment with
daunorubicin activate the de novo ceramide synthesis pathway [55], and may like cisplatin, stimulate sphingomyelin
hydrolysis (32, 33).

Conclusion
Ceramide is a recognized target in oncotherapy. However, in order to obviate the effects of abnormal signaling pathways that result in various mechanisms of
resistance in cancer cells, it has been determined that
activation of several pathways conducive to raising ceramide levels is necessary for successful activation of
apoptosis. The concerted effects on ceramide synthesis,
localization and transport by GT3 and its effects on
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membrane receptors may provide important insight
into the targeted pathways necessary to lead pancreatic
cancer cells to initiate the apoptotic process and guide
the design and development of new therapies for the
treatment of pancreatic cancer.

James H. Quillen College of Medicine, East Tennessee State University,
Johnson City, TN 37614, USA.
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